Innovation in Action
Real-world cases studies, outcomes, and success stories demonstrating how our technology is transforming cancer patient care.
Below are some of the patient case-studies:
Case Study 01
Patient Details
Female
74 yrs
Clinical Presentation
Ca Breast
pT2pNO HR+/ HER2–
Clinical History
Patient underwent surgery.
We advised ONCOTYPE Dx but patient was unaffording.
We needed to decided between adjuvant chemotherapy and hormonal therapy.
Test Result
4 CTCs were found with 1 CTC Cluster indicating highly aggressive disease.
Clinical Outcome
Given her age – it was difficult to tolerate chemo.
4# TC – hormonal therapy X 7.5 yrs
Case Study 02
Patient Details
Male
45 yrs
Clinical Presentation
CA rectum
Clinical History
NACT+RT – Sx- CT (delayed due to myelosuppression).
PET Scan and CTC test done at end of therapy.
Test Result
4 CTCs were found with 1 CTC Cluster indicating highly aggressive disease.
PET Scan confirmed multiple liver mets.
Clinical Outcome
Patient underwent surgery.
Patient was unaffording for chemo and expired shortly.
Case Study 03
Patient Details
Female
60 years
Clinical Presentation
CA Breast ER-/PR-/HER2 3+
Clinical History
Sx-L.MRM-pT2N0
CHEMO-6 #TCH +2 # Herceptin (no funds)- on f/u.
PET Scan and CTC test suggested.
Test Result
2 CTCs were found indicating residual disease.
PET Scan confirmed liver mets.
Clinical Outcome
Meta analysis by TMH suggests that 6 months Herceptin is equal to 12 months.
In this particular case, 6M of Herceptin was not enough as patient developed liver mets.
Case Study 04
Patient Details
Female
60 years
Clinical Presentation
CA Breast
Suspicious lung nodules on PET SCAN
Clinical History
Sx –RT.MRM- pT2N2MO
CHEMO- ACX 4- TH X4 – Herceptin x 17 doses
CTC test was done post surgery and post chemotherapy.
Test Result
2 CTCs were found Surgery.
0 CTCs were found post chemotherapy.
Clinical Outcome
After 17 cycles of Herceptin, since CTC and PET was normal, hence we stopped at 1 yr of therapy.
Case Study 05
Patient Details
Female
64 years
Clinical Presentation
Ca Ovary
Stage IIIC
Clinical History
NACT x 3 #pacli –Carbo - ICS – Adj chemo X 3 # Pacli – Carbo-On f/u
CTC test was suggested post treatment.
Test Result
1 CTC were found in CTC Cluster form indicating aggressive residual disease.
CA125 was within normal limits.
CT scan – local recurrence
Clinical Outcome
Patient was put on Oral Metronomic Chemotherapy (OMCT)
Case Study 06
Patient Details
Female
33 years
Clinical Presentation
Ca Ovary
Stage IIIC
Clinical History
Primary cytoreduction done 4 yrs back.
6 #CT – PACLI-CARBO, counselled but PARPi not available hence didn't go for germline testing.
Patient was monitored with CTC test.
Test Result
2 CTCs were found during monitoring which indicated recurrence • PET CT showed recurrence.
Clinical Outcome
Recurrence in liver, hence surgery repeated.
Lipodox –Carbo x 6 #. Patient was found to be BRCA+. Patient was put on Rucaparib (8 months).
CTC is 0 on follow up.
Case Study 07
Patient Details
Male
33 years
Clinical Presentation
Sigmoid colon with peritoneal metastasis
Clinical History
FOLFOX x 4 # - very good partial response.
SX--HIPEC
FOLFOX X8 # +Bevacizumab maintenance
Patient was monitored with CTC test.
Test Result
1 CTC was found in CTC Cluster form indicating aggressive residual disease.
Recurrence in liver found by PET Scan.
Clinical Outcome
Patient succumbed to disease.
Case Study 08
Patient Details
Female
45 years
Clinical Presentation
Ca Breast TNBC
Clinical History
RT.MRM -pT= 4.5 cm,N0. BRCA +ve
4# AC-T x 4#-XRT to CW/SCF.
1 yr of capecitabine (low dose)
Patient was monitored with CTC test.
Test Result
Longitudinal monitoring by CTC test shows absence of CTCs.
Clinical Outcome
Patient on clinical follow up
Case Study 09
Patient Details
Female
68 years
Clinical Presentation
Ca Breastp
T2N2M0 ,ER+/PR+/HER2+(fish negative)
Clinical History
Acx 4- Taxanes x 12 –XRT to CW/SCF.
Patient monitored with CTC test.
Test Result
After initial treatment, 2 CTCs with 1 CTC Cluster was found.
Clinical Outcome
Treatment was changed to capecitabine + hormonal therapy.
Longitudinal monitoring by CTC test shows absence of CTCs.
Case Study 10
Patient Details
Male
55 years
Clinical Presentation
Ca Colon with solitary liver mets.
Clinical History
NACT- folfirinox x 4#
SX for colon and liver
Adj . FOLFOX X 8#.
Patient monitored with CTC test.
Test Result
Latest CTC test shows, 2 CTCs.
However, both PET and MRI are negative.
There is discordance between CTC and imaging techniques.
Clinical Outcome
Patient on follow up. CTC may be repeated in 3 months.
Case Study 11
Patient Details
Female
50 years
Clinical Presentation
Ca Ovary Stage IIIC
Clinical History
Primary cytoreduction
6# pacli- carbo
Test Result
2 CTCs were found indicating residual disease.
PET Scan confirmed local recurrence.
Clinical Outcome
Patient was put on Oral Metronomic Chemotherapy (OMCT)
Case Study 12
Patient Details
Female
50 years
Clinical Presentation
Ca Breast – RT MRM done
p/w sternal mets and ipsilateral SC LN mets
Clinical History
No chemo/RT/HT taken due to fear
Chemo- AC x 6# - XRT to sternal including Supraclav field
Hormonal therapy x 10 yrs
Test Result
0 CTC were found.
PET Scan confirmed normal
Clinical Outcome
Patient on normal follow up.
Case Study 13
Patient Details
Male
55 years
Clinical Presentation
Ca Breast TNBC
Clinical History
MRM- XRT to CW /SCF
NACT – 4 #AC – Pacli- carbo X 12 #
Capecitabine x 1year
Test Result
From 2 CTCs (1 Cluster) during baseline, CTC first monitoring showed progress with 0 CTCs.
However, latest CTC test shows 1 CTC.
However, both PET and MRI are negative.
Clinical Outcome
Early signs of possible drug resistance. Patient on follow up.
Case Study 14
Patient Details
Female
19 years
Clinical Presentation
Ca Colon
Clinical History
Stage pT4N2
Capox x 8#
Test Result
4 CTCs were found indicating aggressive residual disease.
Recurrence in liver found by PET Scan.
Clinical Outcome
Patient succumbed to disease.
- Page 1
Early detection is half the battle won.
Book a Test
Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists.
Sample Collection
Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 5 ml of patient’s blood sample.
Receive Report
A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site.